Motixafortide

• UNSPSC Description:

  Motixafortide (BKT140 4-fluorobenzoyl) is a novel CXCR4 antagonist with an IC50 vakue of ～1 nM.

• Target Antigen:

  CXCR

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein;Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/BKT140.html

• Purity:

  99.88

• Solubility:

  DMSO : ≥ 100 mg/mL|H2O : 50 mg/mL (ultrasonic)

• Smiles:

  O=C1[C@@]2([H])N(CCC2)C([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CSSC[C@H](NC([C@@H](NC([C@@H](NC([C@@H](N1)CC3=CC=C(C=C3)O)=O)CCCNC(N)=N)=O)CCCNC(N)=O)=O)C(N[C@H](C(N)=O)CCCNC(N)=N)=O)NC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC(C4=CC=C(C=C4)F)=O)=O)=O)CC5=CC6=C(C=CC=C6)C=C5)=O)=O)CC7=CC=C(C=C7)O)=O)CCCNC(N)=O)=O)CCCCN)=O)CCCCN)=O

• Molecular Weight:

  2159.52

• References & Citations:

  [1]Peled A, et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cellsin patients with multiple myeloma. Clin Cancer Res. 2014 Jan 15;20(2):469-79.|[2]Beider K, et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol. 2011 Mar;39(3):282-92.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Clinical Information:

  Launched

• CAS Number:

  664334-36-5